Highlights:
• Fourth consecutive quarter of revenue growth with A$429,700 achieved for Q4 CY20.
• Osteopore achieved revenue of A$1,504,578 for the full 2020 calendar year, marking a 36% increase over CY 2019 results.
• Signed several exclusive Distribution Agreements to promote and sell Osteopore products in Australia and New Zealand, Germany and Austria, Scandinavia, and the Middle East.
• Appointed Ex-ResMed finance executive, Carl Runde, as Chief Financial Officer.
• Recently expanded manufacturing facility now fully operational.
• Cash balance of A$9.0m at 31 December 2020.